Rexahn Pharmaceuticals Granted European Patent for Anti-cancer Compound RX-3117
"In addition to our co-development partnership with Teva, this European patent award further validates the commercial potential of RX-3117," said Dr. Chang Ahn, Rexahn's Chairman and Chief Executive Officer. "The development of RX-3117 strengthens our oncology pipeline, which includes ArchexinTM, currently in Phase II clinical trials."
RX-3117 is a small molecule, new chemical entity (NCE), nucleoside compound that inhibits DNA methyltransferase, a cyclin-dependent kinase, and DNA synthesis. Potential indications of RX-3117 are solid tumors including colon, lung and pancreatic cancers. In preclinical trials, RX-3117 has demonstrated its ability to overcome cancer drug resistance in cancer cells, in particular, gemcitabine-resistance in the human lung cancer cell. The US patent issued for RX-3117 claims composition of matter, synthesis, and methods (2008).
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.